Original Research

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

Patel N, Wu P, Zhang H

Cancer Management and Research 2017, 9:243-248

Published Date: 28 June 2017